GlaxoSmithKline Case Study: Through mergers and acquisitions to success

Published Date: 31/12/2011
Category: Therapies & Markets

Research Report Decription

GlaxoSmithKline is the world’s second largest pharmaceutical company, investing approximately four and a half billion dollars each year on research and development, with an annual turnover reaching £19.2 billion (about $30 billion). The company is headquartered in the UK, with worldwide spread and offices in over 100 countries a.nd major research centers in the UK, USA, Belgium and China.  

This case study gives the insight into the company’s strategy, its assets and strengths and at the same time highlighting its weaknesses.

Key Questions Answered:

• What factors have helped make GSK the second largest pharmaceutical company in the world?
• What is the company’s current and near future strategy?

Companies Mentioned:

GlaxoSmithKline

Paper Highlights:

• Fact-based and presented in an accessible style, they explain the rationale of commercial designs and illustrate wider market and economic trends.

•  Extended R&D and product development is the basic assumption of development in the GSK. The company spends on average over £1.2 billion (approximately $1.9 billion) just on research annually.